On the stock market since 2025, it operates in the world of health and science. It has 11,085 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 9% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The company sells $3.4B a year; the problem isn’t sales — it’s costs running above that number.
It pays out $11.65 per share each year — regular cash for whoever holds the stock.
A loss of $8.6M against $3.4B in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 14/100.
The growth engine is running at low revs right now. Report-card grade: 21/100.
On our five-subject report card, BRKRP sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BRKRP has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.